Trader consensus strongly favors no hantavirus vaccine receiving regulatory approval by the end of 2026, reflected in the 91% market-implied odds for that outcome. This positioning stems from the extended timelines required for vaccine development, where candidates remain in preclinical stages or early Phase 1 trials with no candidates having advanced through Phase 3 testing. Official monitoring shows hantavirus infections remain sporadic, limiting large-scale efficacy studies, while regulatory pathways like FDA review demand years of safety and immunogenicity data. Recent preclinical progress, including DNA-based candidates inducing neutralizing antibodies in small human trials, provides a foundation but faces hurdles in scaling and funding without emergency acceleration. Unexpected outbreaks or major trial breakthroughs could still alter the trajectory before year-end.